| | Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held Virtually, Via Live Webcast at www.virtualshareholdermeeting.com/ | | |
| | The proxy statement and the Form 10-K are available at www.proxyvote.com. | | |
| | You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online at the Annual Meeting, you may vote via the internet, by telephone or, if you receive a paper proxy card, by mailing the completed proxy card. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card. | | |
| | Even if you have voted by proxy, you may still vote online if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must follow the instructions from such organization and will need to obtain a proxy issued in your name from that record holder. | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | | | ||
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | |||
| | ||||||
| | | | | | ||
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | | | ||
| | | | 18 | | | |
| | | | 19 | | | |
| | | | | | ||
| | | | | | ||
| | | | 22 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | |
| | Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. | | |
| | | 1 | | | 2 | | | 3 | | | 4 | | | 5 | | |||||||||||||||
Gender(1) | | | | | M | | | | | | M | | | | | | M | | | | | | F | | | | | | M | | |
African American or Black | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Alaskan Native or American Indian | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Asian | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Hispanic or LatinX | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Native Hawaiian or Pacific Islander | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
White | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Two or more races or ethnicities | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LGBTQ+ | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Did not disclose demographic background | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 2 | | | | | | 4 | | | | | | 0 | | | | | | 0 | | |
Part II: Demographics Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Alaskan Native or Native American | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Asian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Hispanic or Latino | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Native Hawaiian or Pacific Islander | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
White | | | | | 1 | | | | | | 4 | | | | | | 0 | | | | | | 0 | | |
Two or More Races or Ethnicities | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
LGBTQ+ | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Did Not Disclose Demographic Background | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Name | | Audit | | Compensation | | Nominating and Corporate Governance | | | Audit | | Compensation | | Nominating and Corporate Governance | | ||||||||||||||||||||||||
Harrison M. Bains, Jr. | | | | X* | | | | | | | | | | X* | | | | | | | ||||||||||||||||||
Jeffrey L. Ives, Ph.D. | | | | X | | | | | X | | | | | X | | | | | | X | | | | | X | | | | | X | | | ||||||
Martin Vogelbaum | | | | X | | | | | X* | | | | | X* | | | | | | X | | | | | X* | | | | | X* | | | ||||||
Susan Shiff, Ph.D. | | | | | | | | | X | | | | | X | | | | | | | | | | | X | | | | | X | | | ||||||
Total meetings during 2021 | | | | 4 | | | | | 3 | | | | | 0 | | | ||||||||||||||||||||||
Lisa von Moltke, M.D.(1) | | | | | | | | | | | | | | X | | | ||||||||||||||||||||||
Total meetings during 2022 | | | | 4 | | | | | 2 | | | | | 2 | | |
Name | | | Age | | | Position(s) | |
Christopher Posner | | | | | President, Chief Executive Officer and Director | | |
Joana Goncalves, M.D. | | | 49 | | | Chief Medical Officer | |
Ryan Maynard | | | 53 | | | Chief Financial Officer | |
Frédérique Menzaghi, Ph.D. | | | | | Chief Scientific Officer and Senior Vice President, Research and Development | | |
Scott M. Terrillion | | | | | General Counsel, Secretary and Chief Compliance | ||
|
Name | | | Age | | | Position | |
Martin Vogelbaum | | | | | Director | | |
Harrison M. Bains, Jr. | | | | | Director | | |
Jeffrey L. Ives, Ph.D. | | | | | Director | | |
Susan Shiff, Ph.D. | | | | | Director | | |
Lisa von Moltke, M.D. | | | 64 | | | Director | |
Director | | Fees Earned or Paid in Cash(1) | | Stock Awards(2)(4) | | Option Awards(3)(4) | | Total | | | Fees Earned or Paid in Cash(1) | | Stock Awards(2)(4) | | Option Awards(3)(4) | | Total | | ||||||||||||||||||||||||||||||||
Martin Vogelbaum | | | $ | 110,000 | | | | $ | 188,064 | | | | $ | 201,308 | | | | $ | 499,372 | | | | | $ | 115,000 | | | | $ | 299,988 | | | | $ | 199,882 | | | | $ | 614,870 | | | ||||||||
Harrison M. Bains, Jr. | | | | 60,000 | | | | | 94,032 | | | | | 100,654 | | | | | 254,686 | | | | | | 65,000 | | | | | 99,996 | | | | | 99,938 | | | | | 264,934 | | | ||||||||
Jeffrey L. Ives, Ph.D. | | | | 54,250 | | | | | 94,032 | | | | | 100,654 | | | | | 248,936 | | | | | | 67,500 | | | | | 99,996 | | | | | 99,938 | | | | | 267,434 | | | ||||||||
Christopher Posner(5) | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Susan Shiff, Ph.D. | | | | 52,500 | | | | | 94,032 | | | | | 100,654 | | | | | 247,186 | | | | | | 57,500 | | | | | 99,996 | | | | | 99,938 | | | | | 257,434 | | | ||||||||
Lisa von Moltke, M.D. | | | | 8,356 | | | | | 0(5) | | | | | 0(5) | | | | | 8,356 | | |
Director | | | RSUs(a) | | | Number of Shares Underlying Options | | ||||||
Martin Vogelbaum | | | | | | | | | | | | ||
Harrison M. Bains, Jr. | | | | | | | | | | | | ||
Jeffrey L. Ives, Ph.D. | | | | | | | | | | | | ||
Susan Shiff, Ph.D. | | | | | 11,876 | | | | | | 65,796 | | |
Lisa von Moltke, M.D. | | | | | — | | | | | | — | | |
| | Member Annual Service Retainer | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | | Member Annual Service Retainer | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | ||||||||||||||||
Board of Directors | | | $ | 40,000 | | | | $ | 75,000 | | | | | $ | 45,000 | | | | $ | 35,000 | | | ||||
Audit Committee | | | | 10,000 | | | | | 20,000 | | | | | | 10,000 | | | | | 20,000 | | | ||||
Compensation Committee | | | | 7,500 | | | | | 15,000 | | | | | | 7,500 | | | | | 15,000 | | | ||||
Nominating and Corporate Governance Committee | | | | 5,000 | | | | | 10,000 | | | | | | 5,000 | | | | | 10,000 | | |
| What we do: | | | What we do not do: | |
| ✓ Performance metrics tied to ✓ Multi-year vesting ✓ Double-trigger termination ✓ Independent compensation ✓ Independent compensation | | | ✘ No ✘ No special perquisites. Except as otherwise discussed below, we generally do not provide our executives with perquisites or other personal benefits that differ materially from those available to employees generally. ✘ No retirement plans other than 401(k) ✘ No special health or welfare benefits. We do not provide our executives with any special health or welfare benefits. Our executive officers participate in the same broad-based ✘ Hedging, short selling and pledging prohibited. Our insider trading policy prohibits our executive officers and directors from hedging, short selling or pledging our securities. | |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 2022 | | | | | $ | 700,000 | | | | | $ | 200,000(5) | | | | | $ | 407,940 | | | | | $ | 898,280 | | | | | $ | 294,000 | | | | | $ | 9,759 | | | | | $ | 2,509,979 | | |
| | | 2021 | | | | | | 116,167 | | | | | | 268,000 | | | | | | 2,583,896 | | | | | | 6,885,579 | | | | | | — | | | | | | 47,734 | | | | | | 9,901,376 | | | ||
Ryan Maynard(6) Chief Financial Officer | | | | | 2022 | | | | | | 140,600 | | | | | | 8,312(6) | | | | | | — | | | | | | 1,701,405 | | | | | | 38,788 | | | | | | 197 | | | | | | 1,889,302 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Joana Goncalves, M.D. Chief Medical Officer | | | | | 2022 | | | | | | 481,000 | | | | | | 121,860(7) | | | | | | 209,200 | | | | | | 593,904 | | | | | | 134,680 | | | | | | 9,711 | | | | | | 1,550,355 | | |
| | | 2021 | | | | | | 465,000 | | | | | | 93,000 | | | | | | 486,397 | | | | | | 423,776 | | | | | | 257,709 | | | | | | 11,061 | | | | | | 1,736,943 | | |
Executive | | | 2021 Base Salary | | | Percentage Increase in Base Salary from 2020(1) | | ||||||
Christopher Posner | | | | $ | 680,000 | | | | | | —(2) | | |
Derek Chalmers, Ph.D., D.Sc. | | | | | 594,000 | | | | | | 3% | | |
Frédérique Menzaghi, Ph.D. | | | | | 465,000 | | | | | | 3 | | |
Joana Goncalves, M.D. | | | | | 465,000 | | | | | | 3 | | |
Scott Terrillion | | | | | 424,000 | | | | | | 3 | | |
Thomas Reilly | | | | | 412,000 | | | | | | 3 | | |
Named Executive Officer | | | 2023 Base Salary | | | 2022 Base Salary | | | Percentage Increase in Base Salary from 2021(1) | | | 2021 Base Salary | | ||||||||||||
Christopher Posner | | | | $ | 728,000 | | | | | $ | 700,000 | | | | | | 3% | | | | | $ | 680,000 | | |
Ryan Maynard | | | | $ | 478,400 | | | | | $ | 460,000 | | | | | | —(2) | | | | | | — | | |
Joana Goncalves, M.D | | | | $ | 500,240 | | | | | $ | 481,000 | | | | | | 3% | | | | | $ | 465,000 | | |
| | | Target Bonus as Percentage of Base Salary | | | Target Bonus | | ||||||
Frédérique Menzaghi, Ph.D. | | | | | 40% | | | | | $ | 186,000 | | |
Joana Goncalves, M.D. | | | | | 40 | | | | | | 186,000 | | |
Scott Terrillion | | | | | 40 | | | | | | 169,600 | | |
Thomas Reilly | | | | | 40 | | | | | | 164,800 | | |
Named Executive Officer | | | Target Bonus % | | |||
Christopher Posner | | | | | 60% | | |
Ryan Maynard | | | | | 40% | | |
Joana Goncalves, M.D | | | | | 40% | | |
Named Executive Officer | | | 2021 Annual Bonus Payment | | | Percent of Target Bonus | | ||||||
Frédérique Menzaghi, Ph.D. | | | | $ | 167,400 | | | | | | 90% | | |
Joana Goncalves, M.D. | | | | | 167,400 | | | | | | 90 | | |
Scott Terrillion | | | | | 169,600 | | | | | | 100 | | |
Thomas Reilly | | | | | 164,800 | | | | | | 100 | | |
Named Executive Officer | | | 2022 Annual Bonus Payment | | | Percent of Target Bonus | | ||||||
Christopher Posner | | | | $ | 294,000 | | | | | | 70% | | |
Ryan Maynard | | | | $ | 47,100(1) | | | | | | 85% | | |
Joana Goncalves, M.D. | | | | $ | 163,540 | | | | | | 85% | | |
Executive | | | Stock Option Grant (# shares) | | |||
| | | | ||||
| | ||||||
Joana Goncalves, M.D. | | | | | |||
| |
Executive | | | Time-based RSUs (# shares) | | |||
| | | | ||||
| | ||||||
Joana Goncalves, M.D. | | | | | |||
| |
| | | Performance-based RSUs (# shares)(1) | | |||||||||
Executive | | | Target | | | Stretch | | ||||||
Chris Posner | | | | | 65,000 | | | | | | 35,000 | | |
Joana Goncalves, M.D. | | | | | 20,000 | | | | | | 9,000 | | |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Christopher Posner (5) President and Chief Executive Officer | | | | | 2021 | | | | | $ | 116,167(10) | | | | | $ | 268,000(6) | | | | | $ | 2,583,896 | | | | | $ | 6,885,579 | | | | | | — | | | | | $ | 47,734(7) | | | | | $ | 9,901,376 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Derek Chalmers, Ph.D., D.Sc. Former President and Chief Executive Officer | | | | | 2021 | | | | | | 570,062 | | | | | | — | | | | | | 1,665,680 | | | | | | 7,950,174 | | | | | | — | | | | | | 10,869 | | | | | | 10,196,785 | | |
| | | 2020 | | | | | | 576,800 | | | | | | 86,520(8) | | | | | | 818,000 | | | | | | 1,075,130 | | | | | | 346,080 | | | | | | 11,079 | | | | | | 2,913,609 | | | ||
| | | 2019 | | | | | | 560,000 | | | | | | — | | | | | | — | | | | | | 2,551,783 | | | | | | 310,800 | | | | | | 11,034 | | | | | | 3,433,617 | | | ||
| | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||
Thomas Reilly(5) Chief Financial Officer | | | | | 2021 | | | | | | 412,000 | | | | | | 82,400(9) | | | | | | 139,067 | | | | | | — | | | | | | 164,800 | | | | | | 11,736 | | | | | | 810,003 | | |
| | | 2020 | | | | | | 100,000(10) | | | | | | 70,000(11) | | | | | | — | | | | | | 1,417,868 | | | | | | — | | | | | | 590 | | | | | | 1,588,458 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior | | | | | 2021 | | | | | | 465,000 | | | | | | 93,000(9) | | | | | | 486,397 | | | | | | 423,776 | | | | | | 257,709 | | | | | | 11,229 | | | | | | 1,737,111 | | |
| | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 323,349 | | | | | | 10,959 | | | | | | 1,391,310 | | | ||
| | | 2019 | | | | | | 438,000 | | | | | | — | | | | | | — | | | | | | 1,628,797 | | | | | | 148,920 | | | | | | 10,914 | | | | | | 2,226,631 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Joana Goncalves, M.D.(5) Chief Medical Officer | | | | | 2021 | | | | | | 465,000 | | | | | | 93,000(9) | | | | | | 486,397 | | | | | | 423,776 | | | | | | 257,709 | | | | | | 11,061 | | | | | | 1,736,943 | | |
| | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 270,789 | | | | | | 10,911 | | | | | | 1,338,702 | | | ||
| | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||
Scott Terrillion General Counsel, Secretary and Chief Compliance Officer | | | | | 2021 | | | | | | 424,000 | | | | | | 84,800(9) | | | | | | 472,553 | | | | | | 423,776 | | | | | | 169,600 | | | | | | 11,229 | | | | | | 1,585,958 | | |
| | | 2020 | | | | | | 412,000 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 164,800 | | | | | | 11,079 | | | | | | 1,193,681 | | | ||
| | | 2019 | | | | | | 400,000 | | | | | | — | | | | | | — | | | | | | 814,399 | | | | | | 160,000 | | | | | | 11,034 | | | | | | 1,385,433 | | |
| | | | | | | | | Estimated Future Payouts under Non-Equity Incentive Plan Awards(1) | | | Estimated Future Payouts under Equity Incentive Plan Awards(2) | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options(#) | | | Exercise or Base Price of Option Awards ($/Share) | | | Grant Date Fair Value of Stock and Option Awards($)(3) | | ||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Threshold ($) | | | Target (#) | | | Maximum (#) | | | Threshold ($) | | | Target (#) | | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||
Christopher Posner | | | | | 6/3/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,200(4) | | | | | | | | | | | | | | | | | | 94,032 | | |
| | | 6/3/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,800(4) | | | | | | 13.06 | | | | | | 100,654 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 566,000 | | | | | | 16.83 | | | | | | 6,784,925 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,941(5) | | | | | | | | | | | | | | | | | | 100,004 | | | ||
| | | 10/29/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 142,000(6) | | | | | | | | | | | | | | | | | | 2,389,860 | | | ||
Derek Chalmers, Ph.D.., D. Sc. | | | | | 3/30/2021 | | | | | | — | | | | | | 356,400 | | | | | | — | | | | | | 17,333 | | | | | | 52,000 | | | | | | 62,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 52,000(7) | | | | | | | | | | | | | | | | | | 1,070,680 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 103,000 | | | | | | 20.59 | | | | | | 1,364,029 | | | ||
| | | 11/1/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 33,333 | | | | | | | | | | | | | | | | | | 595,000(10) | | | ||
| | | 11/1/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,224,007 | | | | | | | | | | | | 6,586,145(11) | | | ||
Thomas Reilly | | | | | 3/30/2021 | | | | | | — | | | | | | 164,800 | | | | | | — | | | | | | 5,333 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,170(8) | | | | | | | | | | | | | | | | | | 139,067 | | | ||
Frédérique Menzaghi, Ph.D. | | | | | 3/30/2021 | | | | | | — | | | | | | 186,000 | | | | | | — | | | | | | 6,400 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,607(8) | | | | | | | | | | | | | | | | | | 156,957 | | | ||
Joana Goncalves, M.D. | | | | | 3/30/2021 | | | | | | — | | | | | | 186,000 | | | | | | — | | | | | | 6,400 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 12,607(8) | | | | | | | | | | | | | | | | | | 156,957 | | | ||
Scott Terrillion | | | | | 3/30/2021 | | | | | | — | | | | | | 169,600 | | | | | | — | | | | | | 5,333 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | |
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000(9) | | | | | | | | | | | | | | | | | | 329,440 | | | ||
| | | 3/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 20.59 | | | | | | 423,776 | | | ||
| | | 12/17/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 11,495(8) | | | | | | | | | | | | | | | | | | 143,113 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested(#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested($)(2) | | |||||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 8/2/2018 | | | | | | 35,000 | | | | | | — | | | | | | 17.94 | | | | | | 8/2/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/4/2019 | | | | | | 9,000 | | | | | | — | | | | | | 20.47 | | | | | | 6/4/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/4/2020 | | | | | | 10,800 | | | | | | — | | | | | | 15.62 | | | | | | 6/4/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/3/2021 | | | | | | — | | | | | | 10,800(4) | | | | | | 13.06 | | | | | | 6/3/2031 | | | | | | 7,200(5) | | | | | | 87,696 | | | | | | — | | | | | | — | | | ||
| | | 10/29/2021 | | | | | | — | | | | | | 566,000(6) | | | | | | 16.83 | | | | | | 10/29/2031 | | | | | | 147,942(7) | | | | | | 1,801,934 | | | | | | — | | | | | | — | | | ||
Derek Chalmers, Ph.D., D.Sc. Former President and Chief Executive Officer | | | | | 1/30/2014 | | | | | | 80,000 | | | | | | — | | | | | | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 165,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 191,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 225,000 | | | | | | — | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 175,781 | | | | | | 11,719(8) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 161,562 | | | | | | 73,438(8) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 45,833 | | | | | | 54,167(8) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 33,333(8) | | | | | | 405,996 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 19,312 | | | | | | 83,688(8) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 52,000(8) | | | | | | 633,360 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 44,666(8) | | | | | | 544,032 | | | ||
Thomas Reilly Chief Financial Officer | | | | | 10/01/2020 | | | | | | 51,041 | | | | | | 123,959(9) | | | | | | 12.74 | | | | | | 10/1/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,666 | | | | | | 251,712 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,170(10) | | | | | | 136,051 | | | | | | — | | | | | | — | | | ||
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior Vice President, Research and Development | | | | | 1/30/2014 | | | | | | 40,000 | | | | | | — | | | | | | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 60,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 65,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 75,000 | | | | | | — | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 54,140 | | | | | | 3,610(11) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 103,125 | | | | | | 46,875(11) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,400 | | | | | | 199,752 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,607(10) | | | | | | 153,553 | | | | | | — | | | | | | — | | | ||
Joana Goncalves, M.D. Chief Medical Officer | | | | | 10/22/2018 | | | | | | 197,916 | | | | | | 52,084(9) | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | 19,600 | | | | | | 238,728 | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 12,607(10) | | | | | | 153,553 | | | | | | — | | | | | | — | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested(#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested($)(2) | | |||||||||||||||||||||||||||
Scott M. Terrillion General Counsel, Secretary and Chief Compliance Officer | | | | | 11/28/2016 | | | | | | 135,000 | | | | | | — | | | | | | 9.22 | | | | | | 11/28/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/9/2018 | | | | | | 43,593 | | | | | | 2,907(11) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 51,562 | | | | | | 23,438(11) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 14,666 | | | | | | 17,334(11) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,666(12) | | | | | | 129,912 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 6,000 | | | | | | 26,000(11) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 16,000(12) | | | | | | 194,880 | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,666 | | | | | | 251,712 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,495(10) | | | | | | 140,009 | | | | | | — | | | | | | — | | |
| | | Stock Awards | | |||||||||
Name | | | Number of Shares Acquired on Vesting | | | Value Realized on Vesting | | ||||||
| | | (#) | | | ($) | | ||||||
Christopher Posner | | | | | — | | | | | | — | | |
Derek Chalmers, Ph.D., D.Sc. | | | | | 62,751 | | | | | | 1,138,257 | | |
Thomas Reilly | | | | | 5,334 | | | | | | 79,370 | | |
Frédérique Menzaghi, Ph.D. | | | | | 32,934 | | | | | | 586,888 | | |
Joana Goncalves, M.D. | | | | | 25,734 | | | | | | 460,512 | | |
Scott M. Terrillion | | | | | 26,668 | | | | | | 484,030 | | |
Name | | | Benefit | | | Termination without Cause | | | Resignation for Good Reason | | | CIC Termination | | |||||||||
Christopher Posner | | | Severance Payments | | | | $ | 680,000 | | | | | $ | 680,000 | | | | | $ | 1,020,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 47,319 | | | | | | 47,319 | | | | | | 71,979 | | | ||
| Target Bonus | | | | | 408,000 | | | | | | 408,000 | | | | | | 612,000 | | | ||
| Vesting Acceleration(1) | | | | | 592,460 | | | | | | 592,460 | | | | | | 1,889,630 | | | ||
| Benefit Total | | | | $ | 1,727,779 | | | | | $ | 1,727,779 | | | | | $ | 3,593,609 | | | ||
Frédérique Menzaghi, Ph.D. | | | Severance Payments | | | | $ | 348,750 | | | | | $ | 348,750 | | | | | $ | 465,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 1,648 | | | | | | 1,648 | | | | | | 2,198 | | | ||
| Target Bonus | | | | | 186,000 | | | | | | 186,000 | | | | | | 186,000 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 478,345 | | | ||
| Benefit Total | | | | $ | 536,398 | | | | | $ | 536,398 | | | | | $ | 1,131,543 | | | ||
Joana Goncalves, M.D. | | | Severance Payments | | | | $ | 348,750 | | | | | $ | 348,750 | | | | | $ | 465,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 31,932 | | | | | | 31,932 | | | | | | 42,575 | | | ||
| Target Bonus | | | | | 186,000 | | | | | | 186,000 | | | | | | 186,000 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 478,345 | | | ||
| Benefit Total | | | | $ | 566,682 | ��� | | | | $ | 566,682 | | | | | $ | 1,171,920 | | | ||
Thomas Reilly | | | Severance Payments | | | | $ | 309,000 | | | | | $ | 309,000 | | | | | $ | 412,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 31,838 | | | | | | 31,838 | | | | | | 42,450 | | | ||
| Target Bonus | | | | | 164,800 | | | | | | 164,800 | | | | | | 164,800 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 136,051 | | | ||
| Benefit Total | | | | $ | 505,638 | | | | | $ | 505,638 | | | | | $ | 755,301 | | |
Name | | | Benefit | | | Termination without Cause | | | Resignation for Good Reason | | | CIC Termination | | |||||||||
Scott Terrillion | | | Severance Payments | | | | $ | 318,000 | | | | | $ | 318,000 | | | | | $ | 424,000 | | |
| Payment of Employer Health Insurance Continuation | | | | | 32,054 | | | | | | 32,054 | | | | | | 42,739 | | | ||
| Target Bonus | | | | | 169,600 | | | | | | 169,600 | | | | | | 169,600 | | | ||
| Vesting Acceleration(1) | | | | | — | | | | | | — | | | | | | 464,801 | | | ||
| Benefit Total | | | | $ | 519,654 | | | | | $ | 519,654 | | | | | $ | 1,101,140 | | |
| | | Option Awards | | | | | | | | | | | | | | |||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested($)(2) | | |||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 8/2/2018 | | | | | | 35,000 | | | | | | — | | | | | | 17.94 | | | | | | 8/2/2028 | | | | | | — | | | | | | — | | |
| | | 6/4/2019 | | | | | | 9,000 | | | | | | — | | | | | | 20.47 | | | | | | 6/4/2029 | | | | | | — | | | | | | — | | | ||
| | | 6/4/2020 | | | | | | 10,800 | | | | | | — | | | | | | 15.62 | | | | | | 6/4/2030 | | | | | | — | | | | | | — | | | ||
| | | 6/3/2021 | | | | | | 10,800 | | | | | | — | | | | | | 13.06 | | | | | | 6/3/2031 | | | | | | — | | | | | | — | | | ||
| | | 10/29/2021 | | | | | | 141,500 | | | | | | 424,500(3) | | | | | | 16.83 | | | | | | 10/29/2031 | | | | | | 106,500(4) | | | | | | 1,143,810 | | | ||
| | | 2/25/2022 | | | | | | 25,208 | | | | | | 95,792(5) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 39,000(6) | | | | | | 418,860 | | | ||
Ryan Maynard Chief Financial Officer | | | | | 9/12/2022 | | | | | | — | | | | | | 225,000(7) | | | | | | 10.75 | | | | | | 9/12/2032 | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | | | | | | | |||||||||||||||||||||||||||||||||||
Joana Goncalves, M.D. Chief Medical Officer | | | | | 10/22/2018 | | | | | | 250,000 | | | | | | — | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 22,666 | | | | | | 9,334(5) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | 5,333(6) | | | | | | 57,276 | | | ||
| | | 3/30/2021 | | | | | | 14,000 | | | | | | 18,000(5) | | | | | | 20.59 | | | | | | 3/30/2031 | | | | | | 10,666(6) | | | | | | 114,553 | | | ||
| | | 12/17/2021 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,303(8) | | | | | | 67,694 | | | ||
| | | 2/25/2022 | | | | | | 16,666 | | | | | | 63,334(5) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 20,000(6) | | | | | | 214,800 | | |
Year | | | Summary Compensation Table Total for Christopher Posner(1) ($) | | | Summary Compensation Table Total for Derek Chalmers(1) ($) | | | Compensation Actually Paid to Christopher Posner(1)(2)(3) ($) | | | Compensation Actually Paid to Derek Chalmers(1)(2)(3) ($) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) ($) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($) | | | Value of Initial Fixed $100 Investment based on TSR ($)(4) | | | Net Income ($ Millions) | | ||||||||||||||||||||||||
(a) | | | (b) | | | (b) | | | (c) | | | (c) | | | (d) | | | (e) | | | (f) | | | (h) | | ||||||||||||||||||||||||
2022 | | | | | 2,509,979 | | | | | | — | | | | | | 1,365,402 | | | | | | — | | | | | | 1,719,829 | | | | | | 1,953,544 | | | | | | 70.98 | | | | | | (85.5) | | |
2021 | | | | | 9,901,376 | | | | | | 10,196,785 | | | | | | 6,770,961 | | | | | | 3,949,591 | | | | | | 1,467,504 | | | | | | 1,099,179 | | | | | | 80.50 | | | | | | (88.4) | | |
| | 2021 | | | | 2022 | | |
| | Frédérique Menzaghi, Ph.D. | | | | Joana Goncalves, M.D. | | |
| | Joana Goncalves, M.D. | | | | Ryan Maynard | | |
| | Scott Terrillion | | | | | | |
| | Thomas Reilly | | | | | | |
Year | | | Summary Compensation Table Total for Christopher Posner ($) | | | Exclusion of Stock Awards and Option Awards for Christopher Posner ($) | | | Inclusion of Equity Values for Christopher Posner ($) | | | Compensation Actually Paid to Christopher Posner ($) | | ||||||||||||
2022 | | | | | 2,509,979 | | | | | | (1,306,220) | | | | | | 161,643 | | | | | | 1,365,402 | | |
2021 | | | | | 9,901,376 | | | | | | (9,469,475) | | | | | | 6,339,060 | | | | | | 6,770,961 | | |
Year | | | Summary Compensation Table Total for Derek Chalmers ($) | | | Exclusion of Stock Awards and Option Awards for Derek Chalmers ($) | | | Inclusion of Equity Values for Derek Chalmers ($) | | | Compensation Actually Paid to Derek Chalmers ($) | | ||||||||||||
2021 | | | | | 10,196,785 | | | | | | (7,950,174) | | | | | | 1,702,980 | | | | | | 3,949,591 | | |
Year | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) | | | Average Inclusion of Equity Values for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2022 | | | | | 1,719,829 | | | | | | (1,252,255) | | | | | | 1,485,970 | | | | | | 1,953,544 | | |
2021 | | | | | 1,467,504 | | | | | | (713,936) | | | | | | 345,611 | | | | | | 1,099,179 | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Christopher Posner ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Christopher Posner ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Christopher Posner ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Christopher Posner ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Christopher Posner ($) | | | Total – Inclusion of Equity Values for Christopher Posner ($) | | ||||||||||||||||||
2022 | | | | | 1,077,055 | | | | | | (687,305) | | | | | | 155,568 | | | | | | (383,675) | | | | | | 0 | | | | | | 161,643 | | |
2021 | | | | | 6,376,850 | | | | | | 0 | | | | | | 0 | | | | | | (37,790) | | | | | | 0 | | | | | | 6,339,060 | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Derek Chalmers ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Derek Chalmers ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Derek Chalmers ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Derek Chalmers ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Derek Chalmers ($) | | | Total – Inclusion of Equity Values for Derek Chalmers ($) | | ||||||||||||||||||
2021 | | | | | 1,250,106 | | | | | | (467,764) | | | | | | 783,106 | | | | | | 137,532 | | | | | | 0 | | | | | | 1,702,980 | | |
Year | | | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | | | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | | | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | | | Total – Average Inclusion of Equity Values for Non-PEO NEOs ($) | | ||||||||||||||||||
2022 | | | | | 1,527,784 | | | | | | (34,135) | | | | | | 51,435 | | | | | | (59,114) | | | | | | 0 | | | | | | 1,485,970 | | |
2021 | | | | | 432,260 | | | | | | (228,830) | | | | | | 117,823 | | | | | | 24,358 | | | | | | 0 | | | | | | 345,611 | | |
Plan Category | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted- average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted- average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders(1) | | | | 6,464,780 | | | | $ | 15.50 | | | | | 70,157(3) | | | | | | 8,061,962 | | | | $ | 13.69 | | | | | 337,414(3) | | | ||||||
Equity compensation plans not approved by security holders (4) | | | | 47,500 | | | | $ | 25.88 | | | | | 252,500 | | | | | | 0 | | | | $ | 0 | | | | | 300,000 | | | ||||||
Total | | | | 6,512,280 | | | | $ | 15.58 | | | | | 322,657 | | | | | | 8,061,962 | | | | $ | 13.69 | | | | | 637,414 | | |
| | Year ended December 31, | | | Year ended December 31, | | ||||||||||||||||||||
| | 2021 | | 2020 | | | 2022 | | 2021 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit fees(a) | | | $ | 732 | | | | $ | 616 | | | | | $ | 870 | | | | $ | 732 | | | ||||
Tax fees(b) | | | | 15 | | | | | — | | | | | $ | — | | | | | 15 | | | ||||
Total | | | $ | 747 | | | | $ | 616 | | | | | $ | 870 | | | | $ | 747 | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
Vifor (International) Ltd.(1) | | | | | 7,396,770 | | | | | | 13.8% | | |
Blackrock, Inc.(2) | | | | | 7,199,126 | | | | | | 13.4 | | |
The Vanguard Group(3) | | | | | 3,032,762 | | | | | | 5.7 | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Christopher Posner(4) | | | | | 93,193 | | | | | | * | | |
Thomas Reilly(5) | | | | | 82,057 | | | | | | * | | |
Frédérique Menzaghi, Ph.D.(6) | | | | | 567,508 | | | | | | 1.1 | | |
Scott M. Terrillion(7) | | | | | 325,558 | | | | | | * | | |
Joana Goncalves, M.D.(8) | | | | | 282,578 | | | | | | * | | |
Martin Vogelbaum(9) | | | | | 153,860 | | | | | | * | | |
Harrison M. Bains, Jr.(10) | | | | | 132,500 | | | | | | * | | |
Jeffrey L. Ives, Ph.D.(11) | | | | | 90,800 | | | | | | * | | |
Susan Shiff, Ph.D.(12) | | | | | 40,166 | | | | | | * | | |
Derek Chalmers, Ph.D., D.Sc.(13) | | | | | 2,060,905 | | | | | | 3.8 | | |
All current executive officers and directors as a group (9 persons)(14) | | | | | 1,768,220 | | | | | | 3.2% | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
Blackrock, Inc.(1) | | | | | 7,730,529 | | | | | | 14.3% | | |
Vifor (International) Ltd(2) | | | | | 7,396,770 | | | | | | 13.7% | | |
The Vanguard Group(3) | | | | | 3,101,724 | | | | | | 5.7% | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Christopher Posner(4) | | | | | 392,920 | | | | | | * | | |
Ryan Maynard(5) | | | | | 5,062 | | | | | | * | | |
Joana Goncalves, M.D.(6) | | | | | 354,830 | | | | | | * | | |
Martin Vogelbaum(7) | | | | | 212,681 | | | | | | * | | |
Harrison M. Bains, Jr.(8) | | | | | 154,172 | | | | | | * | | |
Jeffrey L. Ives, Ph.D.(9) | | | | | 116,072 | | | | | | * | | |
Susan Shiff, Ph.D.(10) | | | | | 81,705 | | | | | | * | | |
Lisa von Moltke, M.D. | | | | | 0 | | | | | | — | | |
All current executive officers and directors as a group (10 persons)(11) | | | | | 2,341,886 | | | | | | 4.2% | | |